A 62-year-old man who had a 14-year history of diabetes complained of low-grade fever, general malaise, pain of bilateral femurs and hip girdle, and was admitted to our hospital. The diagnosis of polymyalgia rheumatica (PMR) was made from the clinical symptoms, elevated C-reactive protein and erythrocyte sedimentation rate. Electromyography revealed abnormalities that suggested diabetic peripheral neuropathy. However,the abnormalities were improved after starting treatment with corticosteroids (PSL).
Introduction
Polymyalgia rheumatica (PMR) is characterized by symptoms of muscle stiffness, aching and tenderness of the neck, shoulder girdle or pelvic girdle with fever, and the pathogenesis of the disease remains unclear (1) . It mainly affects individuals over the age of fifty years and decreases the range of motion in the shoulders and hip joints. The results of testing rheumatoid factor are usually negative and the erythrocyte sedimentation rate (ESR,^40 mm/h) and acute-phase proteins are generally elevated. Also, a dramatic response to low doses of prednisolone (PSL) are frequently observed in PMR. The presence of other feverish diseases that could explain the symptoms, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), polymyositis (PM)/dermatomyositis (DM), chronic infection, or multiple myeloma, was considered as criteria for exclusion (1) . Giant cell arteritis (GCA)is well knownas one of the complications of polymyalgia rheumatica ( 1 ). These complications are followed by symptomsor signs related to vasculitis involving the cervical, extra-cranial or upper limb arteries causing headaches, scalp tenderness, jaw claudication, swelling of the tongue or limb muscles, visual loss, sore throat, or cough (1, 2) . Electromyographic studies usually shownormal findings in PMRwith GCA.However, peripheral nerve involvement and electromyographic findings of partial denervation have been reported in both temporal arteritis and polymyalgia rheumatica (3) (4) (5) .
Weexamined electrodiagnostic studies of a male with PMR and recognized the presence of peripheral nerve involvement.
The electromyographic abnormalities were quickly responsive to low-dose corticosteroid therapy in spite of the existence of diabetic peripheral neuropathy.
Case Report
A 62-year-old Japanese man with a 14-year history of diabetes was admitted to our hospital on January 12, 1998. In the past, the glycemic control of the patient had been fair (HbAlc level: 6.5-7.5%). He experienced cerebral infarction about 6 years earlier. His father had angina pectoris and brother had essential hypertension and type 2 diabetes mellitus. He had suffered from abdominal pain and diarrhea for a few days, but the symptomsimproved soon after. Then, low-grade fever was present for several days. General malaise and pain of bilateral femurs and pelvic girdle had been present since late December 1997. The symptoms gradually worsened, and fever rose to 38.5°C every day. Early in January 1998, he felt difficulty in walking, and he was referred to our hospital. Onadmission, the palpebral conjunctiva was anemic and he On laboratory data (Table 1) , tests for both urinary sugar and ketone body were positive. White blood cell count (WBC) was increased to 15,700/jil (neutrophil 78%, eosinophil 6.6%), and normocytic and normochromic anemia, and marked thrombocytosis were found. Hypoalbuminemiaas malnutrition and hyponatremia as mild dehydration were also pointed out. The creatinine kinase level was within the normal range, but Creactive protein (CRP) was increased and the erythrocyte sedimentation rate was markedlyelevated. Onserumimmunological examination, perinuclear anti-neutrophil cytoplasmic antibody (P-ANCA) was positive, whereas anti-nuclear antibody and rheumatoid factor were negative. Weinvestigated whether the origin of fever was due to connective tissue disease, malignant neoplasm or some chronic infections, but the cause of the fever remained unclear. Concerning his glycemic control, the HbA,c level was 7.8% on admission. Plasma glucose level was 260 mg/dl on admission, and insulin therapy was started immediately. On neurological examination, nerve conduction velocities were remarkably decreased. Funduscopic examination revealed diabetic proliferative retinopathy, but urinary albumin excretion in the first morning urine (10.6 mg/gCr) and 24 hours creatinine clearance (102 ml/min) were within the normal limit. Figure 1 shows"the clinical course in this case. From the signs of fever, pain on bilateral femurs and hip girdle with severe inflammation, and elevated ESR, he was diagnosed as having PMR,because malignancy and chronic infection were ruled out by the laboratory findings. In this case, GCAwas not found by the clinical examinations. The administration of 15 mg of PSL per day was started from the 16th hospital day, after which his fever quickly disappeared and general malaise and pain on bilateral femurs and hip girdle were markedly diminished after administration of PSL. WBCwas 8,620/|il, and CRP and platelet were decreased to 0.3 mg/dl and 41.8xlO4/(il, respectively, on the 29th hospital day. ESR was also down to 60 mm/h. On the other hand, tumor necrosis factor (TNF)-oc which was considered as the marker of inflammation due to PMR, was elevated to 6.3 pg/ml (normal range: 0.5-3.62 pg/ ml; mean 1.25 pg/ml) on admission, but decreased to 3.7 pg/ ml at discharge. P-ANCAand thrombomodulin were measured as markers of vasculitis and endothelial cell damage, respectively, in the clinical course. These two markers tended to decrease after corticosteroid therapy. The patient was discharged with the treatment of 10 mg of PSL per day. After discharge, the dose of PSL was gradually decreased and stopped, and the clinical symptomsdid not recur for fifteen months without PSL administration.
Electromyographic studies were performed for the purpose of estimating diabetic peripheral neuropathy with Neuropack 2 by Nihon Kohden. The conduction studies of the right medial motor nerve before and after the administration of PSL, as investigated under the same condition and by the same technician, are demonstrated in Fig. 2 . Before the treatment, medial nerve conduction velocity and amplitude by the same stimulation were 48.4 m/sec and 5.20 mV, respectively; however, each was improved to 51.2 m/sec and 6.47 mVon the 15th day after the start of corticosteroid therapy. Furthermore, they were remarkably improved to 53.1 m/sec and 8.40 mV on the 95th day after the start of corticosteroid therapy. All results of electric nerve conduction studies are shownin Table 2 . There were no significant differences in skin temperature or HbAlc level among the three examinations before treatment, on 15th and on the 95th day after the start ofPSL. We recognized that nerve conduction velocity and amplitude were rapidly improved on the 15th day after administration of PSL in both motor and sensory nerves. On the 95th day after starting PSL, the HbA]c level decreased only 0.3%, however, nerve conduction velocity and amplitude were markedly improved. Weobserved that the vibration senses measured with a Vibratory Sensation Meter (TM-3 1A, Medic International, Tokyo) at both internal malleolus were also improved. Wealso investigated electric nerve conduction on the 197th day after termination of corticosteroid therapy, which was not influenced by the corticosteroid. We found the diabetic peripheral neuropa- thy in the patient as a result of the electrodiagnostic study, because nerve conduction velocity remained below the normal range after complete improvement of the inflammation due to PMR.
Discussion
Electrodiagnostic abnormalities were described as an uncommoncomplication in former reviews of polymyalgia rheumatica. However,there are somereports of spontaneous activity and abnormalities of nerve conduction. Buchthal (6) performed quantitative motor unit action potential measurements in six patients with polymyalgia rheumatica and found evidence for myopathy based on the decrease in motor unit duration of more than 20%, and a greater than 12%incidence of polyphagic potential. Bromberg (7) reported in 1990 that two patients with polymyalgia rheumatica achieved remarkable clinical and etectromyographic improvement following corticosteroid therapy. Concerningnerve conduction studies, Schwartz and Brukner (8) reported nerve conduction abnormalities in ll, and small sural potentials in 9 of 14 patients with polymyalgia rheumatica.
In the present case, since the diabetes duration was 14 years, the peripheral nerve involvement had been believed to be due to diabetes mellitus. However, the results of the nerve conduction studies were remarkably improved after corticosteroid therapy without any improvement of glycemic control, and we considered that the majority of peripheral nerve involvement of the patients was due to PMR.
It was reported that the peripheral nerve involvement with PMRmight be induced by vasculitis. Caselli et al (5) found clinical evidence of peripheral neuropathy in 14%in a series of 166 consecutive patients whohad constant GCArecognized by histological evidence. Another report (7) indicated that peripheral nerve involvement with PMR,which was not related to GCA, was improved by treatment with corticosteroids. They suggested that the pathophysiology of neuropathy might not be due to systemic vasculitis, but rather to microvasculitis, causing ischemia in the vasa nervorum around peripheral nerves. Thrombomodulinis thought to be a good indicator of vascular injury (9, 10) . In this case, elevated levels of platelet and thrombomodulin before treatment with PSLwere also found. These data indicated that somevasculitis was presented. Recently, P-ANCAhave been demonstrated in patients with microscopic polyangiitis (MPA), and the autoantibody was definitely diagnostic and had positive pathogenetic significance ( 1 1 , 12) . Since nerve and muscle biopsies were not performed in this case, wecannot demonstrate histological evidence. However, we inferred from positive P-ANCAthat microvasculitis around the peripheral nerves could presumably exist in this case and cause the peripheral nerve involvement. To our best knowledge, there has been no report indicating that peripheral neuropathy with PMRresults from polyangiitis related to P-ANCA. This report was the first to demonstrate that vasculitis with PANCAmight be associated with PMR. Wealso investigated the TNF-oclevel as one of the clinical markers of PMRactivity (13) or insulin resistance (14) . TNFa is one of the inflammatory cytokines, which is produced by PMRwith EMGAbnormalities mononuclear cells (MNCs). Corticosteroids inhibit TNF-oc production by MNCs.The level of serum TNF-oc was elevated in the present patient due to the inflammation from PMR;the treatment with PSL effectively diminished TNF-oc production. The value, however, remained at 5.0 pg/ml on the 197th day after stopping PSL, and this level was higher than the mean serum TNF-a level of healthy individuals. It is known that serum TNFoc levels are also elevated in patients whohave type 2 diabetes with insulin resistance. Therefore, we recognized that the slightly high level of TNF-a might contribute to the insulin resistance due to type 2 diabetes and may not reflect the activity of inflammation, especially microvasculitis around the peripheral nerves, due to PMR. Based on this case, it was suggested that peripheral nerve involvement due to PMRwas improved by the administration of PSLregardless of the existence of diabetic peripheral neuropathy. Weconsidered that the patients with PMRshould be examinedin electromyographicstudies despite the absence of GCA.
